| Bioactivity | VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS)[1]. |
| Target | IC50: 1.59 μM (PDE7), 0.88 μM (GSK-3) |
| Name | VP3.15 |
| CAS | 1281681-54-6 |
| Formula | C20H22N4OS |
| Molar Mass | 366.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Medina-Rodríguez EM, et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep. 2017 Mar 3;7:43545. |
VP3.15
CAS: 1281681-54-6 F: C20H22N4OS W: 366.48
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.